Exploring Lupus Therapeutics Market Trends: Growth Projections and Market Dynamics 2029
Anonymous
59 x views • 3 years ago
The global lupus therapeutics market is set to witness substantial growth in the coming years, fueled by the rising prevalence of lupus disorders and a surge in research and development (R&D) activities. Lupus, particularly systemic lupus erythematosus (SLE), is a chronic autoimmune disease affecting various organs, and its incidence and prevalence have been on the rise worldwide.
Read More: https://www.fairfieldmarketresearch.com/report/lupus-therapeutics-market
According to a study published in the Lupus Science and Medicine journal in April 2021, Europe recorded an estimated incidence rate of 0.3 to 5.1 cases per 100,000 individuals per year and a prevalence rate of 6.5 to 85 cases per 100,000 population in 2020. Additionally, the COVID-19 pandemic has shed light on a potential link between COVID-19 and lupus, with reports suggesting that the viral infection could trigger the development of SLE in certain individuals.
The market growth is further driven by the increasing number of R&D activities and drug approvals. Pharmaceutical companies are investing in the development of advanced technologies and emerging markets, creating promising opportunities for the lupus therapeutics market. Notably, AstraZeneca announced positive results from its TULIP Phase 3 clinical trial program in November 2021, highlighting the efficacy of Anifrolumab (Saphnelo), a human monoclonal antibody, in reducing SLE symptoms.
The systemic lupus erythematosus (SLE) category is expected to dominate the lupus therapeutics market, thanks to the growing number of clinical trials focused on developing treatments for this specific condition. SLE affects multiple organs, causing tissue damage and exhibiting a wide range of clinical symptoms. Key players in the market are actively engaged in providing therapeutics for various lupus conditions, including SLE.
North America currently holds a significant market share, primarily due to the increasing prevalence of lupus in the region and the emphasis placed by major key players on technological advancements. The Lupus Foundation of America reported that nearly 1.5 million people in the US have some form of lupus, with SLE accounting for 70% of cases, and the majority of those affected being women.
Asia-Pacific is projected to experience substantial growth in the forecast period, driven by a growing population, rising healthcare expenditure, and increased research and drug development projects. Companies such as Biocon Biologics Limited in India have initiated clinical studies for potential lupus treatments, such as Itolizumab for Lupus Nephritis, a kidney disease associated with SLE.
The global lupus therapeutics market presents a competitive landscape, with companies introducing new products and forming collaborations to expand their offerings. In January 2022, BenevolentAI expanded its collaboration with AstraZeneca to develop therapeutic medications for SLE and heart failure. Similarly, GlaxoSmithKline received FDA approval in December 2020 for its medicine BENLYSTA, a treatment for SLE-related active lupus nephritis.
Key players in the lupus therapeutics market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
As the prevalence of lupus continues to rise globally, the lupus therapeutics market is poised for substantial growth. Advancements in research, increased investment in R&D, and the development of innovative treatments will provide patients with improved therapeutic options and pave the way for a brighter future in lupus management.
Trending Reports: https://issuu.com/fairfieldmarket/docs/japan_gas_insulated_transformer_market_to_benefit_/s/26828790
Visit Our Blog: https://www.fairfieldmarketresearch.com/blog/the-global-last-mile-delivery-market-a-comprehensively-insightful-overview
For further details, please visit www.fairfieldmarketresearch.com.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Email: [email protected]
Read More: https://www.fairfieldmarketresearch.com/report/lupus-therapeutics-market
According to a study published in the Lupus Science and Medicine journal in April 2021, Europe recorded an estimated incidence rate of 0.3 to 5.1 cases per 100,000 individuals per year and a prevalence rate of 6.5 to 85 cases per 100,000 population in 2020. Additionally, the COVID-19 pandemic has shed light on a potential link between COVID-19 and lupus, with reports suggesting that the viral infection could trigger the development of SLE in certain individuals.
The market growth is further driven by the increasing number of R&D activities and drug approvals. Pharmaceutical companies are investing in the development of advanced technologies and emerging markets, creating promising opportunities for the lupus therapeutics market. Notably, AstraZeneca announced positive results from its TULIP Phase 3 clinical trial program in November 2021, highlighting the efficacy of Anifrolumab (Saphnelo), a human monoclonal antibody, in reducing SLE symptoms.
The systemic lupus erythematosus (SLE) category is expected to dominate the lupus therapeutics market, thanks to the growing number of clinical trials focused on developing treatments for this specific condition. SLE affects multiple organs, causing tissue damage and exhibiting a wide range of clinical symptoms. Key players in the market are actively engaged in providing therapeutics for various lupus conditions, including SLE.
North America currently holds a significant market share, primarily due to the increasing prevalence of lupus in the region and the emphasis placed by major key players on technological advancements. The Lupus Foundation of America reported that nearly 1.5 million people in the US have some form of lupus, with SLE accounting for 70% of cases, and the majority of those affected being women.
Asia-Pacific is projected to experience substantial growth in the forecast period, driven by a growing population, rising healthcare expenditure, and increased research and drug development projects. Companies such as Biocon Biologics Limited in India have initiated clinical studies for potential lupus treatments, such as Itolizumab for Lupus Nephritis, a kidney disease associated with SLE.
The global lupus therapeutics market presents a competitive landscape, with companies introducing new products and forming collaborations to expand their offerings. In January 2022, BenevolentAI expanded its collaboration with AstraZeneca to develop therapeutic medications for SLE and heart failure. Similarly, GlaxoSmithKline received FDA approval in December 2020 for its medicine BENLYSTA, a treatment for SLE-related active lupus nephritis.
Key players in the lupus therapeutics market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
As the prevalence of lupus continues to rise globally, the lupus therapeutics market is poised for substantial growth. Advancements in research, increased investment in R&D, and the development of innovative treatments will provide patients with improved therapeutic options and pave the way for a brighter future in lupus management.
Trending Reports: https://issuu.com/fairfieldmarket/docs/japan_gas_insulated_transformer_market_to_benefit_/s/26828790
Visit Our Blog: https://www.fairfieldmarketresearch.com/blog/the-global-last-mile-delivery-market-a-comprehensively-insightful-overview
For further details, please visit www.fairfieldmarketresearch.com.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Email: [email protected]
